Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art
Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non-small-cell lung cancer (NSCLC) that is currently managed under guidelines used for conventional NSCLC and has poor survival. Surgery is the optimal choice for resectable PSC, and the prevalence of mutations in this type of tumor laid the...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2022-03, Vol.2022, p.8541157-11 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | |
| container_start_page | 8541157 |
| container_title | Journal of oncology |
| container_volume | 2022 |
| creator | Zhang, Lin Lin, Weihao Yang, Zhenlin Li, Renda Gao, Yibo He, Jie |
| description | Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non-small-cell lung cancer (NSCLC) that is currently managed under guidelines used for conventional NSCLC and has poor survival. Surgery is the optimal choice for resectable PSC, and the prevalence of mutations in this type of tumor laid the foundation for novel systemic therapies such as targeted therapy and immunotherapy. PSC is resistant to chemotherapy and radiotherapy, and the effects of the 2 therapies are controversial. Targeted therapies have been reported to confer survival benefits, and savolitinib, an oral selective MET tyrosine-kinase inhibitor, has been approved in metastatic patients with MET exon 14 skipping mutations. Expression and positive rate of programmed death ligand 1 in PSC are high; our previous research has also revealed a high mutational burden and a T-cell-inflamed microenvironment of PSC. Correspondingly, immune checkpoint inhibitors have shown preliminary antitumor effects (overall response rates of 40.5% (15/37) and 31.6% (6/19) in two retrospective studies, respectively) in PSC patients. In summary, patients should receive operations at an early stage and multimodality treatments are needed to maximize the benefits of patients with advanced disease. |
| doi_str_mv | 10.1155/2022/8541157 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8975648</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A699257638</galeid><sourcerecordid>A699257638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-ffd9cceb66e6737cf9575d0226438039de309b92663f6e2867016adb9c51df543</originalsourceid><addsrcrecordid>eNp9kc1LHTEUxYNU1Nruui4D3RTqq5lJcpO4EB6PfghKS9WdEPLyoZGZiWYyiv99M75Xa7twlXuTX849l4PQuxp_rmvG9hvcNPuC0dLwDbRTg-AzQRl-9azeRq-H4RpjoFjCFtomjICQmOygi5OxzaGLVrchP1RnyencuT5X0Vc_x7aLvU4P1alOJnY6x2CrRalDX7qDal79cnfB3U_wYkxp-neadXbTxTzlN2jT63Zwb9fnLjr_-uVs8X12_OPb0WJ-PDOUQ555b6UxbgnggBNuvGSc2bIWUCIwkdYRLJeyASAeXCOA4xq0XUrDausZJbvocKV7My47Z03xkXSrblLoinsVdVD_vvThSl3GOyUkZ0BFEfi4FkjxdnRDVl0YjGtb3bs4Dqo4AUkpUFnQD_-h13FMfVnvkQLCgYu_1KVunQq9j2WumUTVHKRsGAcyUXsryqQ4DMn5J8s1VlO4agpXrcMt-Pvnaz7Bf9IswKcVcBV6q-_Dy3K_AXG7qwQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2646637678</pqid></control><display><type>article</type><title>Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art</title><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zhang, Lin ; Lin, Weihao ; Yang, Zhenlin ; Li, Renda ; Gao, Yibo ; He, Jie</creator><contributor>Cui, Qingbin ; Qingbin Cui</contributor><creatorcontrib>Zhang, Lin ; Lin, Weihao ; Yang, Zhenlin ; Li, Renda ; Gao, Yibo ; He, Jie ; Cui, Qingbin ; Qingbin Cui</creatorcontrib><description>Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non-small-cell lung cancer (NSCLC) that is currently managed under guidelines used for conventional NSCLC and has poor survival. Surgery is the optimal choice for resectable PSC, and the prevalence of mutations in this type of tumor laid the foundation for novel systemic therapies such as targeted therapy and immunotherapy. PSC is resistant to chemotherapy and radiotherapy, and the effects of the 2 therapies are controversial. Targeted therapies have been reported to confer survival benefits, and savolitinib, an oral selective MET tyrosine-kinase inhibitor, has been approved in metastatic patients with MET exon 14 skipping mutations. Expression and positive rate of programmed death ligand 1 in PSC are high; our previous research has also revealed a high mutational burden and a T-cell-inflamed microenvironment of PSC. Correspondingly, immune checkpoint inhibitors have shown preliminary antitumor effects (overall response rates of 40.5% (15/37) and 31.6% (6/19) in two retrospective studies, respectively) in PSC patients. In summary, patients should receive operations at an early stage and multimodality treatments are needed to maximize the benefits of patients with advanced disease.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2022/8541157</identifier><identifier>PMID: 35368903</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Cancer ; Cancer therapies ; Carcinoma ; Chemotherapy ; Disease control ; Drug therapy ; Lung cancer ; Lung cancer, Non-small cell ; Medical prognosis ; Medical research ; Medicine, Experimental ; Radiation therapy ; Radiotherapy ; Respiratory agents ; Review ; Sarcoma ; Surgery</subject><ispartof>Journal of oncology, 2022-03, Vol.2022, p.8541157-11</ispartof><rights>Copyright © 2022 Lin Zhang et al.</rights><rights>COPYRIGHT 2022 John Wiley & Sons, Inc.</rights><rights>Copyright © 2022 Lin Zhang et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022 Lin Zhang et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-ffd9cceb66e6737cf9575d0226438039de309b92663f6e2867016adb9c51df543</citedby><cites>FETCH-LOGICAL-c476t-ffd9cceb66e6737cf9575d0226438039de309b92663f6e2867016adb9c51df543</cites><orcidid>0000-0001-6961-8421 ; 0000-0002-0501-9814</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975648/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975648/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35368903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Cui, Qingbin</contributor><contributor>Qingbin Cui</contributor><creatorcontrib>Zhang, Lin</creatorcontrib><creatorcontrib>Lin, Weihao</creatorcontrib><creatorcontrib>Yang, Zhenlin</creatorcontrib><creatorcontrib>Li, Renda</creatorcontrib><creatorcontrib>Gao, Yibo</creatorcontrib><creatorcontrib>He, Jie</creatorcontrib><title>Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non-small-cell lung cancer (NSCLC) that is currently managed under guidelines used for conventional NSCLC and has poor survival. Surgery is the optimal choice for resectable PSC, and the prevalence of mutations in this type of tumor laid the foundation for novel systemic therapies such as targeted therapy and immunotherapy. PSC is resistant to chemotherapy and radiotherapy, and the effects of the 2 therapies are controversial. Targeted therapies have been reported to confer survival benefits, and savolitinib, an oral selective MET tyrosine-kinase inhibitor, has been approved in metastatic patients with MET exon 14 skipping mutations. Expression and positive rate of programmed death ligand 1 in PSC are high; our previous research has also revealed a high mutational burden and a T-cell-inflamed microenvironment of PSC. Correspondingly, immune checkpoint inhibitors have shown preliminary antitumor effects (overall response rates of 40.5% (15/37) and 31.6% (6/19) in two retrospective studies, respectively) in PSC patients. In summary, patients should receive operations at an early stage and multimodality treatments are needed to maximize the benefits of patients with advanced disease.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma</subject><subject>Chemotherapy</subject><subject>Disease control</subject><subject>Drug therapy</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Respiratory agents</subject><subject>Review</subject><subject>Sarcoma</subject><subject>Surgery</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kc1LHTEUxYNU1Nruui4D3RTqq5lJcpO4EB6PfghKS9WdEPLyoZGZiWYyiv99M75Xa7twlXuTX849l4PQuxp_rmvG9hvcNPuC0dLwDbRTg-AzQRl-9azeRq-H4RpjoFjCFtomjICQmOygi5OxzaGLVrchP1RnyencuT5X0Vc_x7aLvU4P1alOJnY6x2CrRalDX7qDal79cnfB3U_wYkxp-neadXbTxTzlN2jT63Zwb9fnLjr_-uVs8X12_OPb0WJ-PDOUQ555b6UxbgnggBNuvGSc2bIWUCIwkdYRLJeyASAeXCOA4xq0XUrDausZJbvocKV7My47Z03xkXSrblLoinsVdVD_vvThSl3GOyUkZ0BFEfi4FkjxdnRDVl0YjGtb3bs4Dqo4AUkpUFnQD_-h13FMfVnvkQLCgYu_1KVunQq9j2WumUTVHKRsGAcyUXsryqQ4DMn5J8s1VlO4agpXrcMt-Pvnaz7Bf9IswKcVcBV6q-_Dy3K_AXG7qwQ</recordid><startdate>20220325</startdate><enddate>20220325</enddate><creator>Zhang, Lin</creator><creator>Lin, Weihao</creator><creator>Yang, Zhenlin</creator><creator>Li, Renda</creator><creator>Gao, Yibo</creator><creator>He, Jie</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6961-8421</orcidid><orcidid>https://orcid.org/0000-0002-0501-9814</orcidid></search><sort><creationdate>20220325</creationdate><title>Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art</title><author>Zhang, Lin ; Lin, Weihao ; Yang, Zhenlin ; Li, Renda ; Gao, Yibo ; He, Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-ffd9cceb66e6737cf9575d0226438039de309b92663f6e2867016adb9c51df543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma</topic><topic>Chemotherapy</topic><topic>Disease control</topic><topic>Drug therapy</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Respiratory agents</topic><topic>Review</topic><topic>Sarcoma</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Lin</creatorcontrib><creatorcontrib>Lin, Weihao</creatorcontrib><creatorcontrib>Yang, Zhenlin</creatorcontrib><creatorcontrib>Li, Renda</creatorcontrib><creatorcontrib>Gao, Yibo</creatorcontrib><creatorcontrib>He, Jie</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Lin</au><au>Lin, Weihao</au><au>Yang, Zhenlin</au><au>Li, Renda</au><au>Gao, Yibo</au><au>He, Jie</au><au>Cui, Qingbin</au><au>Qingbin Cui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2022-03-25</date><risdate>2022</risdate><volume>2022</volume><spage>8541157</spage><epage>11</epage><pages>8541157-11</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Pulmonary sarcomatoid carcinoma (PSC) is an unconventional non-small-cell lung cancer (NSCLC) that is currently managed under guidelines used for conventional NSCLC and has poor survival. Surgery is the optimal choice for resectable PSC, and the prevalence of mutations in this type of tumor laid the foundation for novel systemic therapies such as targeted therapy and immunotherapy. PSC is resistant to chemotherapy and radiotherapy, and the effects of the 2 therapies are controversial. Targeted therapies have been reported to confer survival benefits, and savolitinib, an oral selective MET tyrosine-kinase inhibitor, has been approved in metastatic patients with MET exon 14 skipping mutations. Expression and positive rate of programmed death ligand 1 in PSC are high; our previous research has also revealed a high mutational burden and a T-cell-inflamed microenvironment of PSC. Correspondingly, immune checkpoint inhibitors have shown preliminary antitumor effects (overall response rates of 40.5% (15/37) and 31.6% (6/19) in two retrospective studies, respectively) in PSC patients. In summary, patients should receive operations at an early stage and multimodality treatments are needed to maximize the benefits of patients with advanced disease.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>35368903</pmid><doi>10.1155/2022/8541157</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-6961-8421</orcidid><orcidid>https://orcid.org/0000-0002-0501-9814</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2022-03, Vol.2022, p.8541157-11 |
| issn | 1687-8450 1687-8450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8975648 |
| source | PubMed Central Open Access; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Cancer Cancer therapies Carcinoma Chemotherapy Disease control Drug therapy Lung cancer Lung cancer, Non-small cell Medical prognosis Medical research Medicine, Experimental Radiation therapy Radiotherapy Respiratory agents Review Sarcoma Surgery |
| title | Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T10%3A24%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multimodality%20Treatment%20of%20Pulmonary%20Sarcomatoid%20Carcinoma:%20A%20Review%20of%20Current%20State%20of%20Art&rft.jtitle=Journal%20of%20oncology&rft.au=Zhang,%20Lin&rft.date=2022-03-25&rft.volume=2022&rft.spage=8541157&rft.epage=11&rft.pages=8541157-11&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2022/8541157&rft_dat=%3Cgale_pubme%3EA699257638%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2646637678&rft_id=info:pmid/35368903&rft_galeid=A699257638&rfr_iscdi=true |